Literature DB >> 19561448

Prevalence and origin of amyloid in kidney biopsies.

Hanna von Hutten1, Michael Mihatsch, Hartmut Lobeck, Birgit Rudolph, Magdalena Eriksson, Christoph Röcken.   

Abstract

We aimed to reassess renal amyloidosis in kidney biopsies with a focus on possibly misclassified or unclassified cases and changes in the prevalence of different amyloid types. Two hundred thirty-three kidney biopsies obtained from 231 patients diagnosed with amyloid during the period from 1990 to 2007 years were included in this retrospective study. Amyloid was identified by Congo red staining and polarization microscopy. Immunohistochemical classification was made with antibodies directed against AA amyloid, apolipoprotein A1, fibrinogen, lysozyme, lambda-light chain, kappa-light chain, beta2-microglobulin, transthyretin, and amyloid P-component. Amyloid was present in each biopsy as vascular, tubulo-interstitial and/or glomerular deposits. Immunoglobulin light chain-derived (AL) amyloidosis was most prevalent and diagnosed in 123 (53.2%) patients. It was categorized into AL amyloid of lambda-light chain (ALlambda) [105 (85.4%) patients] and kappa-light chain origin (ALkappa) [10 (8.1%)]. The amyloid deposits of 8 (6.5%) patients were not clearly distinguishable into ALlambda amyloid or ALkappa amyloid and categorized as AL amyloid, not otherwise specified. Reactive systemic amyloid A (AA) amyloidosis was the second most common type and was found in 93 patients (40.3%). Overall 7 patients were found to suffer from fibrinogen A alpha-chain-[amyloid of fibrinogen (AFib); 4 (1.7%) patients], transthyretin-[amyloid of transthyretin (ATTR); 2 (0.9%)], or apolipoprotein A1-derived (AApoAI) amyloidosis [1 (0.4%)]. In 8 patients (3.4%) the amyloid deposits remained unclassifiable. After additional immunostaining and further clinical information the diagnoses of 12 patients (5.1%) were modified (2 ALlambda amyloid, 4 ALkappa amyloid, 1 amyloid unclassified, 3 mixed-type amyloidosis, AA+ATTR, ALlambda+ATTR, and ALkappa+ATTR, 1 AFib, and 1 AApoAI). Although the histologic and immunohistochemical reevaluation confirmed the classifications in 221 (95.7%) patients. Renal amyloidosis is most commonly of ALlambda-origin, followed by AA amyloidosis. AFib amyloidosis was found to be the most prevalent type of hereditary renal amyloidosis, illustrating the necessity of a thorough classification of the amyloid proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19561448     DOI: 10.1097/PAS.0b013e3181abdfa7

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  23 in total

Review 1.  Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics.

Authors:  Samih H Nasr; Ahmet Dogan; Christopher P Larsen
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-14       Impact factor: 8.237

Review 2.  [Update on immunohistological classification of amyloidoses].

Authors:  C Röcken
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

3.  Renal ApoA-1 amyloidosis with Glu34Lys mutation and intra-amyloid lipid accumulation.

Authors:  Nicole K Andeen; Daniel Y Lam; Ian H de Boer; Roberto F Nicosia
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Amyloid in endomyocardial biopsies.

Authors:  Barbara Kieninger; Magdalena Eriksson; Reinhard Kandolf; Philipp A Schnabel; Stefan Schönland; Arnt V Kristen; Ute Hegenbart; Peter Lohse; Christoph Röcken
Journal:  Virchows Arch       Date:  2010-04-08       Impact factor: 4.064

5.  Renal amyloidosis caused by apolipoprotein A-II without a genetic mutation in the coding sequence.

Authors:  Ryuji Morizane; Toshiaki Monkawa; Konosuke Konishi; Akinori Hashiguchi; Mitsuharu Ueda; Yukio Ando; Hirobumi Tokuyama; Koichi Hayashi; Matsuhiko Hayashi; Hiroshi Itoh
Journal:  Clin Exp Nephrol       Date:  2011-07-05       Impact factor: 2.801

6.  Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series.

Authors:  Charles L Murphy; Shuching Wang; Daniel Kestler; Christopher Larsen; Don Benson; Deborah T Weiss; Alan Solomon
Journal:  Am J Kidney Dis       Date:  2010-10-16       Impact factor: 8.860

7.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Nelson Leung; Lynn D Cornell; Mary E Fidler; Loren Herrera Hernandez; Julie A Vrana; Jason D Theis; Patrick S Quint; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

Review 8.  [Causes and treatment of systemic amyloidosis].

Authors:  N Blank; U Hegenbart; S Schönland
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

9.  Review of eprodisate for the treatment of renal disease in AA amyloidosis.

Authors:  Adam Rumjon; Thomas Coats; Muhammad M Javaid
Journal:  Int J Nephrol Renovasc Dis       Date:  2012-02-24

10.  Epidemiological, clinical and laboratorial profile of renal amyloidosis: a 12-year retrospective study of 37 cases.

Authors:  Elissa Oliveira da Fonseca; Porphirio Jose Soares Filho; Licinio Esmeraldo da Silva; Maria Lucia Ribeiro Caldas
Journal:  J Nephropathol       Date:  2015-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.